Introduction
The data on beneficial effects of magnesiumtreatment in patients who suffered aneurysmal subarachnoid hemorrhage (SAH) is conflicting.
Experimental results in cerebral ischemia [1] [2] [3] [4] and early clinical data in stroke patients [5, 6] supported the idea that magnesium may act as a neuroprotective agent in cerebral ischemia and SAH. In the last two decades, several clinical studies have shown beneficial effects of magnesium in SAH [7] [8] [9] [10] [11] [12] [13] [14] . However, two large multicenter trials failed to confirm a reduced incidence of delayed cerebral ischemia and an improvement of clinical recovery by intravenous administration of magnesium sulfate [15, 16] and caused some disillusionment. However, the results of these two large studies may have been influenced by the co-medication. In both trials nimodipine was co-administered as a standard medication to magnesium-treated patients as well as to patients of the control-groups. Similar to nimodipine, magnesium predominantly acts as a calcium antagonist. This co-treatment resembles a combination therapy consisting of two similarly acting substances which is, from a pharmacological point of view, unlikely to exert synergistic effects. From the database of a clinical trial, which we previously reported on [14] , we conducted this analysis focusing on the potential neuroprotective effects of continuous highdose administration of magnesium sulfate during episodes of neurological deterioration, arterial vessel narrowing, or abnormalities in perfusion imaging suggesting a critical brain perfusion.
Materials and Methods
The study was approved by the local ethics committee. Informed consent was obtained from the patient or from a permanent or temporary legal guardian. This is a posthoc analysis from a randomized clinical trial comparing the effects of intravenous magnesium sulfate versus control in patients after aneurysmal SAH [14] . For this purpose, critical events in terms of delayed ischemic neurological deterioration (DIND), angiographic delayed vasospasm, abnormal findings in Perfusion-CT (PCT) and elevated mean flow velocities (MFV) in transcranial Doppler sonography (TCD) were analyzed. magnesium or control group, respectively, developed secondary infarction after these episodes of critical brain perfusion or not.
Inclusion-and exclusion-criteria
Patients were included if they had suffered aneurysmal SAH within 96 hours before admission and no history of prior bleeding.
In-and exclusion criteria have previously been described in detail [14] . All patients were admitted to the neurosurgical intensive care unit of a university hospital. All patients underwent 
Target parameters
The target parameter was secondary infarction on native CT within the following three days after episodes that suggest critical brain perfusion:
1.
An episode of DIND, CT-scans were analyzed for new hypodensities.
Secondary infarction on plain CT-scans were defined as described by von Kummer et al. [19] .
Data analysis A Fisher exact test was used to analyze
incidences. An ROC analysis was performed We found a tendency towards a slightly lower heart rate in magnesium-treated patients, 
Transcranial Doppler Sonography (TCD)
In the magnesium group, 114 TCD measurements showed elevated MFV. Of those, 7 were followed by secondary infarction. In the control-group, 135 TCD-measurements showed elevated MFV, 32 were followed by secondary infarction (p = 0.0009).
Perfusion-CT (PCT)
In all but 2 cases, Flow-Perfusion maps and Blood Volume maps showed defects which correlated with already demarcated infarction in native CT. In the magnesium group, 117
Time-To-Peak (TTP) maps showed abnormal findings. 10 of those were followed by In SAH, in turn, the prerequisites for a neuroprotective treatment are different. infarction [14] . Recently, the topic of magnesium has been re-caught and in an intraoperative setting during aneurysm surgery, the CBFincreasing properties been demonstrated [25] . In addition, further experimental [26] and clinical data [27] [28] [29] has been published suggesting a dose-dependent neuroprotective effect of parenteral magnesium.
In the face of these new activities in the was not beyond any doubt since the benefit of treatment is largely determined by one trial [30, 31] . The magnesium doses used in both trials were markedly lower than in our study in which 140 ± 51 mmol/d were administered to maintain the target serum parameters. In fact, dose regimens were used in those trials that had previously failed to prove a neuroprotective effect in stroke patients [32] and were neither tested in experimental settings nor in earlier clinical trials before launching the randomized trial. It is well known that magnesium has clear dose dependent effects [33] . New experimental data emphasizes that a neuroprotective action may not be exerted below a certain concentration [26] . Therefore, plasma concentrations need to be high enough. Our study used higher doses than other trials (Table   2 ) and -although it is a monocenter study -is the only one to investigate a dosing schedule that was a) controlled by serum levels, and b) tested for its neuroprotective efficacy in a preclinical experimental setting. antagonists [14] .
The fact that it resembles an incidentrelated rather than a patient-related analysis is a limitation of this study. A patient-related analysis has been reported previously [14] . It was, therefore, our purpose to investigate the tissue-protective effect of the compound once a sign of critical brain perfusion has appeared. References
